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ABSTRACT
Data presented here extends our previous observa-
tions on a-globin transcriptional regulation by the
CP2 and PIAS1 proteins. Using RNAi knockdown,
we have now shown that CP2b, CP2c and PIAS1
are each necessary for synergistic activation of en-
dogenous a-globin gene expression in differenti-
ating MEL cells. In this system, truncated PIAS1
mutants lacking the ring finger domain recruited
CP2c to the nucleus, as did wild-type PIAS1,
demonstrating that this is a sumoylation-
independent process. In vitro, recombinant CP2c,
CP2b and PIAS1 bound DNA as a stable CBP
(CP2c/CP2b/PIAS1) complex. Following PIAS1
knockdown in MEL cells, however, the association
of endogenous CP2c and CP2b with the a-globin
promoter simultaneously decreased. By mapping
the CP2b- and CP2c-binding domains on PIAS1,
and the PIAS1-binding domains on CP2b and
CP2c, we found that two regions of PIAS1 that
interact with CP2c/CP2b are required for its
co-activator function. We propose that CP2c,
CP2b, and PIAS1 form a hexametric complex with
two units each of CP2c, CP2b, and PIAS1, in which
PIAS1 serves as a clamp between two CP2 proteins,
while CP2c binds directly to the target DNA and
CP2b mediates strong transactivation.
INTRODUCTION
Transcription factor CP2c, a member of the CP2 gene
family, participates in diverse processes, including hem-
atopoiesis, immune response, the cell cycle and neural
development, by regulating expression of speciﬁc target
genes (1). The ubiquitous expression of CP2c has drawn
attention to its regulatory mechanisms in various cellular
and developmental contexts. Interactions between CP2c
and cell-restricted factors may determine the speciﬁcity
of target gene expression. In erythroid cells, CP2c interacts
with an erythroid-speciﬁc factor, NF-E4, to form a
stage-selector protein complex that binds to and activates
the g-globin promoter (2–4). The zinc ﬁnger transcription
factor GATA-1, expressed within the hematopoietic
system, interacts with CP2c to bind to adjacent
CP2/GATA-1 sites within the promoters of GATA-1,
NF-E4 and EKLF genes (5). Interaction between CP2c
and the neuron-speciﬁc protein Fe65 blocks cell cycle pro-
gression by downregulating thymidylate synthase gene ex-
pression (6,7).
Many transcription factors exist in families of isoforms
with distinct activities generated by alternative splicing, or
by gene duplication and diversiﬁcation during evolution.
Heteromeric combinations of isoforms exert diﬀerent
eﬀects on target genes, leading to various cellular re-
sponses. The CP2 transcription factor family, with six
human isoforms (LBP-1a, -1b, -1c, -1d, -9 and -32) and
four murine (CP2a/NF2d9, CP2b, CP2c/CP2 and CRTR),
exempliﬁes this pattern (1). CP2c was initially identiﬁed as
an activator of the murine a-globin gene that binds to the
consensus sequence CNRG-N6-CNR(G/C) within the
a-globin promoter (8–12). Indeed, overexpression of
CP2c strongly activates the a-globin promoter in vitro
and in vivo (10,11). Furthermore, experimental CP2c de-
pletion suppresses a- and ß-globin gene transcription, and
hemoglobin synthesis during terminal diﬀerentiation of
murine erythroid leukemia (MEL) cells (13). A novel
CP2 isoform, CP2b, is identical to CP2a except for an
additional 36 amino acids encoded by an extra exon that
gives an additional transcriptional activation domain.
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a-globin expression (14). Investigations with exogenous
CP2 proteins reveal that CP2a and CP2b localize exclu-
sively in the cytoplasm and nucleus, respectively (15).
Following knockdown of CP2a/CP2b, cells retain CP2c
in the cytoplasm. However, in cells that coexpress CP2b,
exogenous CP2c localizes predominantly in the nucleus,
whereas in cells that coexpress CP2a, CP2c remains in
the cytoplasm. Since each CP2 family protein may form
homo- and heterodimers and/or oligomers (16,17), it is
postulated that CP2c may localize in either the nucleus
or the cytoplasm, depending on the relative levels of
CP2a and CP2b. In this context, CP2b would potentiate
erythroid cell-speciﬁc a-globin expression by recruiting
CP2c into the nucleus (15). In addition, the heteromeric
complex of CP2b and CP2c activates a-globin in an eryth-
roid cell-speciﬁc manner; that is, the dimer activates the
a-globin promoter in erythroid K562 and MEL cells, but
not in non-erythroid 293T cells (14). Finally, we identiﬁed
PIAS1 (protein inhibitor of activated STAT1), as an inter-
active partner to CP2 proteins and a potent co-activator
for CP2c/CP2b-mediated a-globin expression in erythroid
cells (14).
The PIAS protein family includes at least ﬁve evolution-
arily conserved genes and/or splice variants (PIAS1,
PIAS3, PIASxa, PIASxb and PIASy) (18). Mammalian
PIAS proteins were initially identiﬁed as negative regula-
tors of STAT signaling (19,20), but may interact with
more than 70 proteins. One major function of these
proteins is the control of gene transcription (21). PIAS
proteins can act as either an activator or a repressor, de-
pending on the target gene or interactions with transcrip-
tional regulators (18,21,22). PIAS proteins can also act as
small ubiquitin-like-modiﬁer (SUMO) E3 ligases (23),
because they share the central RING-ﬁnger domain
(RFD, amino acids 309–400) required for SUMO E3
ligase activity (21,24). This ﬁnding sheds light on the
mechanistic role of sumoylation in transcriptional regula-
tion by the PIAS proteins. Sumoylation aﬀects the stabil-
ity (25), subcellular localization (26,27) and activity of
PIAS target proteins (21,28–31), which include c-Jun,
p53, lymphoid enhancer factor 1, Smad, androgen
receptor and GATA4. Transcription factors comprise
the largest group of proteins subject to sumoylation,
although some transcription factors are not coupled to
this function (18,21,32,33).
Here, we report that PIAS1 induces the movement of
CP2c from the cytoplasm to the nucleus, which may be
required to activate CP2c/CP2b-mediated a-globin expres-
sion. In addition, we found that PIAS1 stabilizes the
CP2c/CP2b complex and strongly enhances its recruit-
ment to consensus binding sites within the a-globin
promoter, through interaction with CP2 proteins. Two
PIAS1-binding regions were mapped in both CP2c and
CP2b. The N-terminal and C-terminal halves of PIAS1
also interact with CP2c and CP2b, and both regions are
required for PIAS1 to function as a co-activator. An
RFD-deleted PIAS1 mutant interacts with CP2 proteins
to enhance a-globin transcription by increasing the DNA
binding activity of the CP2c/CP2b complex. These data
suggest that PIAS1 functions as a clamp for formation of
an active CBP (CP2c/CP2b/PIAS1) complex, conferring
DNA-binding activity on the CP2c/CP2b complex.
MATERIALS AND METHODS
Cell culture
The murine erythroid leukemia (MEL) cell line DS19 was
cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM,
Gibco BRL) supplemented with 10% fetal bovine serum
(Hyclone), 50U/ml penicillin, and 50mg/ml streptomycin
(Gibco BRL). Terminal diﬀerentiation of MEL cells was
induced by supplementation with hexametylene-bis-
acetamide (HMBA, 5mM). Human myelogenous
leukemia K562 cells were maintained in RPMI 1640
(Gibco BRL) supplemented with 10% fetal bovine
serum (Hyclone). The human embryonic kidney cell line
293T was maintained in DMEM plus 10% fetal bovine
serum (Hyclone).
Plasmid construction
Full-length cDNAs of mouse CP2a and CP2b were cloned
into the pEGFPN1 vector (Clontech) yielding the expres-
sion plasmids pEGFPN1-CP2a and pEGFPN1-CP2b,
respectively. The pEGFPN1-CP2c, pCMV-HA CP2c,
pCMV-HA CP2b and pcDNA3-FLAG-PIAS1 plasmids
have been described previously (14). Truncation mutants
were generated from pGEX2TK-PIAS1 (a gift from
Dr. Guntram Suske), pGEX-4T2 CP2b and pGEX-4T2
CP2c (14). Both pcDNA3-PIAS1 (1-480, c-FLAG) and
pcDNA3-PIAS1 (400-651, c-FLAG) were kind gifts
from Dr. Wilson Xu. A polymerase chain reaction
(PCR) product encoding amino acids 1–320 of PIAS1
was inserted into pcDNA3-FLAG (Invitrogen), to which
PCR products corresponding to amino acids 394–540 and
394–651 were ligated in frame to make pcDNA3-
Flag-PIAS1 1-540 (RFD) and PIAS1 1-651 (RFD).
The pcDNA3-FLAG-PIAS1-pseudo vector was generated
by substitution of a full-length cDNA of glutathione-
S-transferase for amino acids 135–400 of PIAS1. All
DNA sequences used for vector construction were con-
ﬁrmed by sequencing. To generate the small hairpin
RNA (shRNA) speciﬁc for CP2c, an oligonucleotide
(50-GGG CCC GAA TGC TAG ACA ATA GAA TTC
AAG AGA TTC TAT TGT CTA GCA TTC GTT
TTT-30, italics indicate sequences speciﬁc for CP2c) was
inserted downstream of the U6 promoter of a pGEM-T
vector. The PIAS1 oligonucleotide sequences used to con-
struct mouse and human PIAS1 shRNA expression
vectors were mPIAS1i,5 0-CAT TCC ACA GCT CAC
TTA-30; and hPIAS1i,5 0-CAT TCC ACA ACT CAC
TTA-30. To generate the shRNA speciﬁc for human
LBP-1a/b, an oligonucleotide (LBP-1a/bi,5 0-GAT CCC
CCA GAC TTC TTG ATT TAG ATT TCA AGA GAA
TCT AAA TCA AGA AGT CTG TTT TT-30, italics
indicate the sequence speciﬁc for LBP-1a/b) was inserted
downstream of the H1 promoter of a pLV-TH vector
(a gift from Dr. Didier Trono).
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The synthetic siRNAs targeting mouse CP2b, CP2c and
PIAS1 were purchased from Dharmacon. The siRNA se-
quences are (sense strand indicated): siCP2a/b, 50-GAU
GCU GGA UAA UCG CAA A-30; siCP2c, 50-CGG
UGA AGC UCC ACG ACG A-30; and siPIAS1,
50-GGA AUA AGG AAU CCG GAU C-30. MEL DS19
cells were transfected with siRNAs (at a ﬁnal concentra-
tion of 100nM) in Opti-MEM (Gibco) using
Lipofectamine 2000 (Invitrogen) repeatedly at intervals
of 17h, according to the manufacturer’s protocol. We
used non-targeting siRNA (Dharmacon, D-001810-01)
as a negative control. After the second transfection, cells
were treated with 5mM HMBA for 24h to induce diﬀer-
entiation and then harvested for RNA or protein
preparation.
Transfection and luciferase assays
A luciferase reporter construct containing the mouse
a-globin promoter was constructed using a pGL3-TATA
A vector, as previously described (14). K562 and MEL
cells (2 10
4/well) were plated in 24-well dishes. DNA
(400–600ng), including both the luciferase reporter con-
struct and CP2 expression vectors in various combin-
ations, was transiently transfected using Eﬀectene
(Qiagen), according to the manufacturer’s recommenda-
tions. 293T cells (5 10
4) were plated in 24-well dishes,
and DNA (2mg), including the reporter and CP2 expres-
sion vectors, was transiently transfected using the calcium
phosphate method. Cells were harvested 48h after trans-
fection in 100ml passive lysis buﬀer (Promega), and 20ml
of lysate was used for luciferase assays on a Lumat
LB9501 luminometer (Berthold). A dual-luciferase assay
system (Promega) was used according to the manufactur-
er’s instructions, and ﬁreﬂy luciferase expression was
normalized against renilla luciferase. All experiments
were repeated at least three times independently.
Expression of GST-fusion proteins and
aﬃnity chromatography
GST-fusion proteins for deletion mutants of CP2 isoforms
and PIAS1 were expressed in Escherichia coli BL21.
Fusion proteins were puriﬁed using glutathione-
Sepharose (Amersham-Pharmacia), and their integrity
was conﬁrmed by Coomassie blue staining and western
blotting. For in vitro protein–protein interaction assays,
glutathione-Sepharose beads were incubated with GST
or GST-fusion proteins at 4 C for 1h. After washing,
the beads were resuspended in 100ml binding buﬀer
(20mM Tris–HCl, pH 8.0, 100mM NaCl, 1mM EDTA,
1% NP-40, 0.1% SDS), including protease inhibitor
cocktail (Roche), and then incubated at 4 C for 2h with
whole lysate from 293T cells transfected with
pCMV-HA-CP2c, pEGFPN1-CP2b or pcDNA3-FLAG-
PIAS1. After extensive washing, retained proteins were
eluted by boiling in SDS protein-loading buﬀer and
analyzed by western blotting using anti-HA (Santa
Cruz Biotechnology), anti-FLAG (Sigma), anti-EGFP
(Clontech) or anti-GST antibodies.
Western blotting and immunocytochemistry
Cell extracts were prepared using lysis buﬀer (20mM Tris–
HCl, pH 7.4, 150mM NaCl, 5mM EDTA, 1mM
b-mercaptoethanol, 10% glycerol, 1% NP40, 0.1% SDS,
0.1mM phenylmethylsulfonyl ﬂuoride, 1mM NaF, 1mM
Na3VO4). Whole cell extract proteins (10–30mg) were
electrophoresed on 10% SDS-PAGE gels and transferred
to a nitrocellulose membrane (Bio-Rad). The membrane
was blocked and incubated with appropriate dilutions of
the primary antibody at room temperature for 1h. After
washing, a 1:5000 dilution of the appropriate secondary
antibody (horseradish peroxidase-conjugated) was added
at room temperature for 1h. Polyclonal anti-b-tubulin
antibody (Santa Cruz Biotechnology) was used as a
loading control for immunoblotting. Proteins were
visualized by chemiluminescence using an ECL system
(Amersham-Pharmacia). For immunocytochemisty, 293T
cells were transiently transfected with pEGFPN1-CP2c,
pEGFPN1-CP2b and pcDNA3-FLAG-PIAS1, singly or
in combinations, and ﬁxed at 48h after transfection.
Subcellular localization of each of the CP2 isoforms was
visualized using a ﬂuorescent microscope (Fluoview,
Olympus). To analyze the distribution patterns of green
ﬂuorescent fusion proteins, 293T cells were seeded onto
cover glasses and grown to 50–60% conﬂuence. At 48h
after transfection, cells were ﬁxed in 50% methanol/
acetone at room temperature for 5min and then washed
with phosphate-buﬀered saline (PBS). Over 500 cells
showing enhanced green ﬂuorescent protein (EGFP) ex-
pression were observed and classiﬁed into three groups,
i.e. with ﬂuorescent proteins in the nucleus, cytosol, or
in both nucleus and cytosol. Nuclei were identiﬁed by
Hoechst 33258 staining. To analyze the eﬀect of PIAS1
on CP2 isoform localization, full-length FLAG-PIAS1 or
FLAG-tagged deletion mutants of PIAS1 were transiently
transfected into 293T cells with an expression vector con-
taining the EGFP-fused CP2 isoform. Cells were treated
with mouse-anti FLAG (Sigma), followed by Cy5-
conjugated anti-mouse antibody (Zymed). To analyze
the eﬀect of CP2b and PIAS1 on the localization of en-
dogenous CP2c, MEL and K562 cells transfected with
siCP2a/b, siPIAS1 or siControl RNA were analyzed
by immunostaining of cells with anti-CP2c antibody
(Abcam). Cytospin preparations of MEL and K562 cells
were made on poly-L-lysine-coated slide glasses by
spinning for 3min at 113g under medium acceleration in
a Cytospin 4 cytocentrifuge (Shandon).
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed,
as previously described (34), with some modiﬁcations.
To initiate protein–DNA cross-linking, MEL DS19 cells
(0.6 to 2 10
7 cells) were incubated with formaldehyde at
a ﬁnal concentration of 1% for 7min at room temperature
with gentle agitation. Glycine (0.125M) was added to
quench the reaction. Cells were washed and harvested in
cold 1X PBS, and the pellet was lysed in 1ml cold nuclear
lysis buﬀer [50mM Tris, pH 8.0, 10mM EDTA, 1% SDS,
1X protease inhibitor cocktail (Roche)], then diluted to
2ml with IP dilution buﬀer [20mM Tris, pH 8.0,
5458 Nucleic Acids Research, 2010,Vol.38, No. 16150mM NaCl, 2mM EDTA, 0.01% SDS, 1% Triton
X-100, 1X protease inhibitor cocktail (Roche)]. The
lysate was sonicated with 10 rounds of 20s each at 70%
of maximum output using an ultrasonic processor H200
(Dr Hielscher, Germany). Soluble chromatin was
precleared by addition of 200ml protein A-Sepharose
beads (50% slurry in IP dilution buﬀer; GE Healthcare).
An aliquot of precleared chromatin was removed (input
control), and the remainder of the chromatin was
incubated with anti-CP2b (custom antibody obtained
from Peptron), anti-CP2c (13), and anti-PIAS1-speciﬁc
antibodies (Abcam) overnight at 4 C. Normal rabbit
IgG (Santa Cruz) served as a negative control. Immune
complexes were collected by incubation with 30ml protein
A-Sepharose for 2h at 4 C. The precipitates were washed
twice with IP buﬀer (20mM Tris, pH 6.8, 150mM NaCl,
2mM EDTA, 0.1% SDS, 1% TritonX-100, 0.5X protease
inhibitor cocktail), once with LiCl wash buﬀer (50mM
Tris, pH 8.0, 250mM LiCl, 1mM EDTA, 1% NP40,
0.5% deoxycholate, 0.5X protease inhibitor cocktail),
and twice with Tris-EDTA buﬀer. Immune complexes
were eluted twice with 200ml elution buﬀer (0.1M
NaHCO3, 1% SDS). The eluate and input control were
reverse cross-linked at 65 C for 5h and treated with
RNase A and proteinase K individually. DNA was
puriﬁed by phenol/chloroform extraction and the Phase
Lock Gel system (5 Prime). Puriﬁed DNA was analyzed
by real-time quantitative PCR using primers covering the
mouse a-globin promoter (forward: 50-GGT TTG AGG
GAC TTG CTT CT-30 and reverse: 50-GGT AGA GCA
AGC ACA AAC CAG-30).
Electrophoretic mobility shift assay
Nuclear extracts were prepared from 293T cells trans-
fected with expression vectors for HA-tagged CP2
isoforms, FLAG-tagged PIAS1 truncation/deletion
forms, or a control vector, as described previously (14).
Each of the nuclear extracts was incubated individually or
in various combinations in 25-ml reactions containing
100mM KCl, 10mM Tris–HCl, pH 7.9, 1mM EDTA,
1mM DTT, 4% glycerol, 0.1% NP-40, 1mg poly dI dC
(Pharmacia), and a
32P-labeled oligonucleotide probe. The
probe DNA corresponded to the CP2c consensus binding
sites in the mouse a-globin promoter: 50-GAT CCC AAG
TTT TAC TCG GTA GAG CAA GCA CAA ACC
AGG-30 ( 156 to  124 from the start codon). The
reaction mixtures were separated on native 5% polyacryl-
amide gels, and the dried gels were autoradiographed. The
same procedure was used for the puriﬁed GST-CP2c,
GST-CP2b and GST-PIAS1. For supershift analysis,
3mg anti-CP2c, anti-CP2b, anti-PIAS1 antibody, or IgG
was added to the reaction mixture.
Real-time quantitative reverse transcription (RT)-PCR
Total RNA was isolated using Trizol reagent (Invitrogen).
RNA (300ng) was reverse transcribed by incubation with
10pmol random hexamer and 100U M-MLV reverse
transcriptase (Invitrogen). cDNA was analyzed by
real-time PCR, which was performed using SYBR
premix ExTaq (Takara) and the Light Cycler 1.5 system
(Roche). For RT-PCR, the following primers were used:
mCP2b, forward 50-GCC AGA GAA TCA CCG TAG
TC-30 and reverse 50-GCT TGT GCA GCT CCA TCT
CC-30; mCP2c, forward 50-CGT ACC TCA ATC AAG
GAC AG-30 and reverse 50-CGG AAT ATG CTC TTC
ACC AG-30; mPIAS1, forward 50-TGC CTT GAC ACC
ACA AC-30 and reverse 50-GCT TTG GTT CCA CAC
CG-30; mGAPDH, forward 50-CGT GCC GCC TGG
AGA AAC C-30 and reverse 50-TGG AAG AGT GGG
AGT TGC TGT TG-30; and ma-globin, forward 50-GCT
GCC TGG GGG AAG ATT GG-30 and reverse 50-GCA
GGC AGT GGC TCA GGA GC-30. All ampliﬁcations
were performed in triplicate. The expression ratio was
calculated using the manufacturer’s software (Lightcycler
4.1) with GAPDH as the internal reference gene.
Statistical analysis
Data are expressed using the mean and the standard de-
viation when at least two independent experiments were
performed. Student’s t-test was used for performing
analysis of variance in Excel software. A P-value of 0.05
or less was considered statistically signiﬁcant.
RESULTS
CP2c, CP2b and PIAS1 are indispensable for
erythroid-speciﬁc a-globin expression
We reported previously that CP2c, CP2b and PIAS1 bind
together to the a-globin promoter in vivo and that PIAS1
strongly enhances CP2c/CP2b complex-mediated a-globin
gene activation (14). To identify components of the CBP
complex that are essential for a-globin gene activation, we
tested the eﬀects of knockdown of each protein, using an
RNAi-based gene targeting strategy. Expression plasmids
for individual CP2 isoforms (HA-CP2c and HA-CP2b)
and PIAS1 (FLAG-PIAS1) were transfected into K562
cells, along with a reporter plasmid encoding a luciferase
gene controlled by the mouse a-globin promoter
(Figure 1A). Coexpression of CP2c, CP2b and PIAS1 in
K562 cells induced synergistic increases of a-globin gene
expression, as previously described (Figure 1A, lanes 2–5).
These transactivation eﬀects were signiﬁcantly decreased
by expression of speciﬁc shRNAs for CP2 isoforms (CP2ci
or CP2a/bi) or PIAS1 (PIAS1i), in a dose-dependent
manner (Figure 1A, lanes 6, 7, 9, 10, 12 and 13). Protein
levels of CP2 isoforms and PIAS1 in cells with or without
the shRNA constructs were measured by western blotting
to ensure that the decreased luciferase activity was actually
due to altered CP2 and PIAS1 levels (Figure 1A, right
panel).
To determine which proteins are necessary for a-globin
gene expression in erythroid diﬀerentiation, the eﬀects
of shRNA-induced knockdown of endogenous CP2c,
CP2a/b and PIAS1 were examined in diﬀerentiating
MEL cells by the reporter assays. Knockdown of CP2c,
CP2a/b or PIAS1 protein in diﬀerentiating MEL cells
reduced the a-globin promoter activity to a basal level,
whereas transfection of the empty vector (mock) or the
EGFP shRNA expression vector did not aﬀect the
a-globin promoter activity (Figure 1B).
Nucleic Acids Research, 2010,Vol.38, No. 16 5459To conﬁrm the knockdown eﬀect of CP2c, CP2b or
PIAS1 on endogenous a-globin expression in erythroid
diﬀerentiation, we transfected siRNAs speciﬁc for each
of these genes [CP2c, CP2b, PIAS1 (siCP2c, siCP2a/b,
siPIAS1)] or control siRNAs (siControl) into MEL cells.
After two rounds of siRNA transfection, erythroid diﬀer-
entiation was induced by incubating the MEL cells in
HMBA (5mM) for 24h. Total RNA and whole lysates
were prepared from the transfected cells for real-time
quantitative reverse transcription (qRT-PCR) and
western blotting, respectively. We conﬁrmed speciﬁc de-
creases in CP2b, CP2c or PIAS1 expression at the levels of
mRNA and protein [Figure 1C, (b) and (c)]. The level of
a-globin mRNA in knocked-down MEL cells was
compared to that in the control [Figure 1C, (a)].
Knockdown of CP2b, CP2c or PIAS1 decreased
a-globin transcription signiﬁcantly in diﬀerentiating
MEL cells. Cells transfected with siPIAS1 showed the
greatest inhibition of a-globin gene expression ( 50%).
These data imply that all three factors are required for
a-globin gene expression in erythroid cell diﬀerentiation
in vivo.
PIAS1 directs CP2c to the nucleus
The subcellular localization of a transcription factor
complex responds dynamically to intracellular conditions,
with corresponding changes in binding aﬃnity for speciﬁc
promoters (35–37). We showed previously that nuclear
localization of CP2c depends on the relative cellular
A
R
e
l
a
t
i
v
e
 
l
u
c
i
f
e
r
a
s
e
 
a
c
t
i
v
i
t
y
E
G
F
P
i
P
I
A
S
1
i
C
P
2
c
i
p
G
L
3
-
T
A
T
A
HMBA
HMBA
(–)
(+)
C
P
2
a
/
b
i
M
o
c
k
a-globin promoter
0
2
4
6
8
10
HA-CP2c
HA-CP2b
FLAG-PIAS1
PIAS1i
CP2a/bi
CP2ci
+ + + + + + ++ ++ ++
+++ + + + + + + + ++
++ ++ ++ + + + + + +
-- - - - - -
--- - - --
--- --- -
-+-+
--+ +
-++-
----
----
----
FLAG-PIAS1
HA-CP2b
B
R
e
l
a
t
i
v
e
 
l
u
c
i
f
e
r
a
s
e
 
a
c
t
i
v
i
t
y
0
1
2
3
4
5
6
7
1       2       3       4          5       6       7           8 9       10         11      12     13        
-+
FLAG
HA
Tubulin
-+
CP2a/bi
HA
CP2ci
HA-CP2c
-+
Tubulin
Tubulin
CP2b
CP2c
PIAS1
Tubulin
siCP2b
siCP2c
siPIAS1
siControl
(c)
PIAS1i
R
e
l
a
t
i
v
e
 
a
-
g
l
o
b
i
n
 
e
x
p
r
e
s
s
i
o
n
  (a)
C
1.2
1
0.8
0.6
0.4
0.2
0
siCP2b siCP2c siPIAS1 siControl
R
e
l
a
t
i
v
e
 
e
x
p
r
e
s
s
i
o
n
 
(b)
1.2
1
0.8
0.6
0.4
0.2
0
siCP2b siCP2c siPIAS1 siControl
CP2b
CP2c
PIAS1
Figure 1. CP2c, CP2b and PIAS1 are essential for maximal upregulation of a-globin expression in erythroid cells. (A) K562 cells were transiently
transfected with a luciferase reporter vector driven by the mouse a-globin promoter along with expression vectors, as indicated. At 48h after
transfection, whole cell lysates were prepared, and ﬁreﬂy and Renilla luciferase activities were measured simultaneously. Average values and standard
deviations were obtained from three independent experiments. One-tenth (20mg) of each whole cell extract was analyzed on a western blot with
anti-FLAG or anti-HA antibody, and with b-tubulin as a control. (B) A reporter vector containing the a-globin promoter was transiently
cotransfected with RNAi expression vectors speciﬁc for EGFP, CP2c, CP2a/b or PIAS1 into MEL cells in the absence or presence of 5mM
HMBA, as indicated. Each value was measured, as described in (A). (C) Eﬀects of knockdown of endogenous CP2b, CP2c or PIAS1 on
a-globin gene induction in diﬀerentiating MEL cells. MEL cells were transfected with siRNAs speciﬁc for CP2b, CP2c or PIAS1 (siCP2b, siCP2c
and siPIAS1) and control siRNA (siControl). After 24h of HMBA treatment, total RNA was isolated and analyzed by real-time qRT-PCR.
(a) Expression of the a-globin gene relative to that of the GAPDH gene is shown. Values were normalized to results obtained from cells transfected
with an siControl. Gene-speciﬁc decreases in expression corresponding to each siRNA were conﬁrmed at the levels of mRNA and protein, using
real-time qRT-PCR (b) and western blotting (c). Expression of CP2b, CP2c and PIAS1 genes relative to that of the GAPDH gene are shown, with
values normalized as in (a). (c) Proteins (10mg) were analyzed on western blots with anti-CP2b, anti-CP2c, anti-PIAS1 and anti-tubulin antibodies
(as a control).
5460 Nucleic Acids Research, 2010,Vol.38, No. 16levels of CP2a and CP2b, with CP2b recruiting CP2c into
the nucleus, and CP2a holding CP2c in the cytoplasm by
direct protein–protein interaction (15).
In the presence of CP2c and CP2b, PIAS1 synergistic-
ally enhances a-globin expression (see Figure 1) (14),
which led us to ask whether PIAS1 also aﬀects the
subcellular localization of CP2c. In 293T cells, exogenous
PIAS1 displayed a punctuate distribution within the
nucleus (Figure 2A, upper panel), as reported for other
cell types (29,30), whereas CP2b localized exclusively in
nucleus and CP2c in both nucleus and cytoplasm,
(Figure 2A, middle panel). Consistent with previous data
for the physical interaction between CP2c and PIAS1 (14),
immunocytochemical data showed that, when coexpressed
with PIAS1, CP2c localized concurrently in both the
nucleus and cytoplasm in 50% of cotransfected cells
(Figure 2B). We observed that CP2c always colocalized
with PIAS1 in the nucleus (Figure 2A, bottom panel).
Thus, the nuclear recruitment of CP2c by PIAS1 stands
in parallel to the previous ﬁnding that CP2b induces the
nuclear localization of CP2c (15). In addition, even with
depletion of LBP-1a/b (a human homolog of CP2a/b) in
293T cells, PIAS1 still enhanced the movement of CP2c to
the nucleus (Figure 2B). These ﬁndings indicate that
PIAS1 induces the nuclear localization of CP2c in a
CP2b-independent way.
To verify the dependence of CP2c nuclear localization
on CP2b and/or PIAS1, we examined the localization of
CP2c in MEL cells with endogenous CP2b and/or PIAS1
knocked down using siRNA (Figure 3). MEL cells were
transfected with siRNAs speciﬁc for CP2a/b, or PIAS1
(siCP2a/b, and siPIAS1) and scrambled siRNA
(siControl) and induced to diﬀerentiate by treatment
with HMBA for 24h. Western blots showed that endogen-
ous CP2b and PIAS1 proteins were reduced by more than
50% in an siRNA-speciﬁc manner, with no eﬀect on the
level of CP2c expression [Figure 3A, (b)]. CP2c localized
in the nucleus more prominently in siControl-transfected
cells, and both in the nucleus and cytoplasm in siCP2a/b-
or siPIAS1-transfected cells [Figure 3A, (a)]. CP2c
localized more prominently in cytoplasm in the
knockdown of both CP2a/b and PIAS1. Similar results
were obtained in K562 cells (Figure 3B). These data cor-
relate well with the results in Figure 2 that show that both
PIAS1 and CP2b direct CP2c to the nucleus. Furthermore,
since the PIAS1 level increased about 4-fold during MEL
cell diﬀerentiation, as did other CP2 isoforms
(Supplementary Figure S1), our data suggest that CP2b
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Nucleic Acids Research, 2010,Vol.38, No. 16 5461and PIAS1 enhance a-globin expression in erythroid dif-
ferentiation by inducing the movement of CP2c to the
nucleus.
PIAS1 forms a complex with CP2c/CP2b and enhances
the DNA-binding activity of the CP2c/CP2b complex
Since PIAS1 acts as an interacting partner with CP2
proteins and as a co-activator for CP2c/CP2b-mediated
a-globin expression in erythroid cells (14), we
hypothesized that PIAS1 might be required to modulate
DNA binding activity of the CP2c/CP2b complex at the
a-globin promoter. We tested the eﬀect of PIAS1 on DNA
binding of the CP2 complex using recombinant CP2c,
CP2b and PIAS1 in electrophoretic mobility shift assay
(EMSA) (Figure 4A). PIAS1 strongly enhanced the
DNA-binding activity of the CP2 complex, which other-
wise would bind negligibly to the a-globin promoter
(compare lanes 8 and 9 to lanes 10 and 11). PIAS1 did
not aﬀect the DNA-binding activity of CP2c alone (lanes
12 and 13), nor did it bind directly to the a-globin
promoter (lanes 6 and 7). However, migration of the
protein–DNA complex, including CP2c, CP2b and
PIAS1, did not diﬀer from that of CP2c alone (compare
lane 3 to lanes 10 and 11). We also observed this phenom-
enon in the reactions containing nuclear extracts of MEL,
K562 or 293T cells (data not shown; see also reference 14).
To test whether the protein–DNA complexes in the
reaction containing CP2c, CP2b and PIAS1 still retained
all three proteins, supershift EMSA analyses were
performed using factor-speciﬁc antibodies (Figure 4B).
The speciﬁcities of the anti-CP2b and CP2c antibodies
were conﬁrmed by western blotting [Figure 4B, right
side of (a)]. In EMSA with nuclear extracts of MEL
cells at diﬀerentiation Day 2, protein–DNA complexes
were shifted upward by the addition of PIAS1 antibody
and did not appear with the addition of anti-CP2b or
anti-CP2c antibodies, whereas IgG produced no change
[Figure 4B, (a)]. These data suggest that the protein–
DNA complexes contained at least one each of the
CP2c, CP2b and PIAS1 proteins. Similar results were
obtained in the reactions using recombinant CP2c, CP2b
and PIAS1 proteins [Figure 4B, (b)]. In addition, when
nuclear extracts prepared from 293T cells transiently
cotransfected with pcDNA3-FLAG-PIAS1, pcDNA3-
HA-CP2c and pEGFPN1-CP2b vectors were subjected
to Co-IP experiments using speciﬁc antibodies, all three
proteins co-precipitated (Figure 4C). These data together
imply that PIAS1 increases the DNA-binding aﬃnity of
the CP2c/CP2b complex for the a-globin promoter
through cooperative binding with both CP2c and CP2b
proteins. Hereafter, we refer to this protein complex as
CBP (CP2c/CP2b/PIAS1).
To conclusively demonstrate the eﬀect of PIAS1 on the
DNA-binding activity of the CP2c/CP2b complex, we
used ChIP to analyze the endogenous target gene
promoter in the presence or the absence of PIAS1
during MEL cell diﬀerentiation (Figure 5). First, we
tested the association of PIAS1, CP2c and CP2b at the
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Figure 3. The localization of CP2c in MEL (A) and K562 (B) cells in which the endogenous PIAS1 and/or CP2a/b were knocked down using
siRNAs. (A) MEL cells were transfected with siRNAs speciﬁc for CP2a/b, or PIAS1 (siCP2a/b, and siPIAS1) and control siRNA (siControl).
(a) After treatment with HMBA for 24h, cells were harvested, attached to glass slides using cytospin and analyzed for CP2c by immunocytochem-
istry. Nuclei were identiﬁed by Hoechst 33258 staining. (b) An aliquot of each cell preparation (a) was analyzed via western blot to conﬁrm protein
levels following knockdown. (B) K562 cells were transfected with the same siRNAs shown in (A) and analyzed for CP2c by immunocytochemistry.
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analysis (Figure 5A). Immunoprecipitation was performed
using antibodies against CP2c, CP2b and PIAS1, with
normal rabbit IgG as a control. The relative occupancy
of CP2c, CP2b and PIAS1 at the a-globin promoter in
diﬀerentiating MEL cells was determined by comparison
to the IgG (control) measurements. Consistent with the
previous ChIP observation (14), all three proteins bound
to the a-globin promoter, and their associations were
enhanced during diﬀerentiation of MEL cells.
Occupancy of CP2c at the a-globin promoter increased
4-fold from Day 1 of diﬀerentiation (Figure 5A).
Recruitment of CP2b and PIAS1 to the a-globin
promoter was also observed in samples where a-globin
expression was active. Notably, the associations of CP2c
and PIAS1 with the promoter were saturated at diﬀeren-
tiation Day 1, whereas CP2b occupancy continued to
increase until Day 2 (Figure 5A), although all of these
proteins continued to increase in expression until Day 2
of diﬀerentiation [Supplementary Figure S1a]. These
results provide strong evidence that all of the CBP
complex proteins are associated with the a-globin
promoter, and this association correlates with a-globin
expression during erythroid diﬀerentiation.
Since PIAS1 co-localized with CP2c/CP2b at the
a-globin promoter (Figure 4), and since this association
increased during MEL cell diﬀerentiation (Figure 5A), we
hypothesized that PIAS1 would be involved in forming a
stable CBP complex in this setting. Accordingly, we tested
whether CP2b or CP2c binds in vivo to the a-globin
promoter in MEL cells following knockdown of PIAS1.
After transfecting PIAS1-speciﬁc siRNA (siPIAS1) or
scrambled siRNA (siControl) into MEL cells, we
compared the relative occupancy of CP2b, CP2c and
PIAS1 at the a-globin promoter between control cells
and cells with PIAS1 knocked down. Indeed, knockdown
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CP2c antibodies were tested by western blotting [(a), right]. Custom peptide antibody was prepared using CP2b peptide
(271-LTEMRLEPIIEDAVEHEQKKSSKRTLPADYGDSLAKRGS-309). The HA-CP2b or HA-CP2c expression vector was transfected into
293T cells, and total lysates were prepared. Proteins (10mg) were analyzed by western blotting with anti-CP2b or anti-CP2c antibody. (C) 293T
cells were transiently cotransfected with pcDNA3-FLAG-PIAS1, pcDNA3-HA-CP2c and pEGFPN1-CP2b vectors. Cell lysates prepared from these
cells were immunoprecipitated using IgG, anti-FLAG, anti-HA or anti-EGFP antibody, and precipitates were analyzed in western blot assays using
antibodies to EGFP, FLAG or HA.
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CP2c to the a-globin promoter in diﬀerentiating MEL
cells (Figure 5B), coincident with suppression of the
gene’s induction [Figure 1C, (a)]. This ﬁnding suggests
that PIAS1 acts as a clamp holding CP2b and CP2c,
which stabilizes the CBP complex at the a-globin
promoter and activates the transcriptional potential of
CP2 proteins.
Two separate regions of each factor in the CBP complex
engage in mutual interactions
To deﬁne the mutual interactions among CP2c, CP2b
and PIAS1 in the CBP complex, we mapped
the CP2c/CP2b-binding domains on PIAS1, and the
PIAS1-binding domains on CP2c and CP2b. We
anticipated that there would be two interacting regions
in each of the factors if PIAS1 functions as a clamp to
hold CP2c and CP2b together. We constructed a series of
deletion mutants of PIAS1, CP2b and CP2c and then per-
formed GST pull-down assays (Supplementary Figure S2).
Puriﬁed recombinant GST-PIAS1 fusion proteins bound
to glutathione beads were incubated with cell extracts con-
taining overexpressed CP2c or CP2b proteins. Analyses of
truncated PIAS1 proteins showed that either of two
domains in the N-terminus and C-terminus was suﬃcient
for the interaction with both CP2c and CP2b (Figure 6A
and Supplementary Figure S2A). A small domain in the
N-terminus (amino acids 1–70, PS1) is suﬃcient for
binding to both CP2b and CP2c. However, in the
C-terminal region, the CP2b-binding domain (PL8) is
larger than the CP2c-binding domain (PL6). Similarly,
analyses of truncated CP2c proteins revealed that two in-
dependent regions of CP2c (CS2, amino acids 134–244;
CL5, amino acids 306–502) were required to interact
with PIAS1 (Figure 6B and Supplementary Figure S2B).
In CP2b, two independent regions (BS7, amino acids
134–251; BS4, amino acids 272–309) were also shown to
interact with PIAS1 (Figure 6C and Supplementary
Figure S2C). Taken together, these ﬁndings suggest that
the physical association of factors comprising the CBP
complex involve two separate regions of each factor.
PIAS1 functions as a clamp for CP2b and CP2c, to
enhance DNA binding and transcriptional activation
To test whether PIAS1 mutants containing a CP2-binding
domain can recruit CP2c into the nucleus, we analyzed the
eﬀects of various PIAS1 truncation mutants, including
PIAS1 mutants lacking the RFD, on the subcellular local-
ization of CP2 proteins (Figure 7A). Although the RFD of
PIAS1 is essential for its sumoylating activity (18,38), it is
not involved in the nuclear localization of PIAS1 (32). All
of the mutant PIAS1 proteins tested localized in the
nucleus in 293T cells (Figure 7B, left panel). When the
CP2c or CP2b expression vectors were cotransfected
with the PIAS1 mutants, FLAG-PIAS proteins containing
the N-terminus (PIAS1 1-480 or PIAS1 1-309) or
C-terminus (PIAS1 400-651) induced movement of CP2c
into the nucleus, and also co-localized with some of the
CP2c and most of the CP2b in the nucleus (Figure 7B,
middle panel). FLAG-PIAS1 mutant proteins defective
in sumoylation due to the RFD deletions [PIAS1
1-651(RFD) and PIAS1 1-540(RFD)] also co-localized
with both CP2c and CP2b in the nucleus (data not shown).
In addition, the PIAS1 hybrid [PIAS1 pseudo
(135-400)], which contained a GST peptide linker
between the two minimal CP2c/CP2b binding regions in
both the N-terminus and C-terminus of PIAS1,
co-localized with both CP2c and CP2b in the nucleus
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Figure 5. CP2b, CP2c and PIAS1 assemble concurrently at the a-globin promoter, and PIAS1 is essential for CP2b and CP2c to bind to the a-globin
promoter. (A) ChIP-real-time qPCR analysis of the endogenous a-globin promoter in diﬀerentiating MEL cells. The relative occupancy of CP2b,
CP2c and PIAS1 at the a-globin promoter in diﬀerentiating MEL cells is shown in comparison to the IgG (control) samples. Values represent the
averages of three independent experiments. Mouse Nanog primers were used as a negative control for all real-time qPCR (data not shown).
(B) Eﬀects of PIAS1 knockdown on the association of CP2b and CP2c with the a-globin promoter in diﬀerentiating MEL cells. PIAS1-speciﬁc
siRNA (siPIAS1) or scrambled siRNA (siControl) was transfected into MEL cells. The relative occupancy of CP2b, CP2c and PIAS1 at the a-globin
promoter was compared between PIAS1-knockdown and control cells. Results represent an average of two independent experiments. The decrease in
PIAS1 protein was conﬁrmed in siPIAS1-treated cells using western blotting.
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Nucleic Acids Research, 2010,Vol.38, No. 16 5465(Figure 7B, right panel). However, it is noteworthy that
the localization phenotype of the full-length protein diﬀers
from that of the truncation mutants, which is much more
diﬀuse within the nucleus. The overall data suggest that
the PIAS1 mutants containing at least one CP2-binding
domain can mobilize CP2c into the nucleus.
To test whether these PIAS1 mutant proteins can serve
as coactivators of CP2c/CP2b-mediated a-globin gene
transcription, we performed reporter assays with CP2b
and CP2c on the a-globin promoter using the full-length
or deletion mutant PIAS1 (Figure 7C). Interestingly, the
PIAS1 mutant containing both the N- and C-terminal
CP2-binding regions (PIAS1 1-480) enhanced
transcriptional activity of the reporter gene, whereas
PIAS1 mutants containing either the N- or C-terminal
CP2c/CP2b binding domain (PIAS1 1-309 and PIAS1
400-651) did not. These data suggest that the PIAS1 trun-
cation mutants containing one CP2c/CP2b binding site
can direct movement of CP2c into the nucleus or
co-localize with CP2b by protein–protein interaction,
but cannot join with the CP2 proteins in target gene acti-
vation because the mutants cannot perform the clamping
function that holds CP2c and CP2b together. In support
of this hypothesis, the RFD deletion mutant [PIAS1
1-540(RFD)], containing two CP2c/CP2b binding
sites, enhanced reporter gene transcription (Figure 7C).
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5466 Nucleic Acids Research, 2010,Vol.38, No. 16The PIAS1 hybrid [PIAS1 pseudo (135-400)] also signiﬁ-
cantly enhanced reporter gene transcription, although the
level of enhancement did not reach that of wild type
PIAS1. To test whether the PIAS1 pseudo (135-400)
mutant binds with and activates a CBP complex at the
promoter, we performed EMSA using extracts of 293T
cells transiently transfected with CP2c, CP2b and PIAS1
pseudo (135-400) expression vectors. As shown in a (a)
of Figure 7D, the PIAS1-pseudo (135-400) mutant
enhanced DNA-binding activity of the CBP complex,
although the level of enhancement was somewhat lower
than with the full-length PIAS1. In support of this, the
addition of the PIAS1-pseudo (135-400) mutant to the
reaction enhanced the protein–DNA complex formation
in EMSA [Figure 7D, (b)]. However, other truncation
mutants (PIAS1 1-480, 400-651) did not aﬀect the
binding activity of CP2c/CP2b complex. This ﬁnding is
consistent with the requirement for both CP2c/
CP2b-interactive regions of PIAS1 in the transactivation
function. Thus, the PIAS1 truncation mutants with only
one of the CP2c/CP2b binding sites exclude either CP2c or
CP2b from the protein–DNA complex formation. Note,
on the other hand, that the PIAS1 1-480 mutant shows no
clamping function in EMSA, but strong transactivation
activity in the reporter assay [compare lane 4 in Figure
7C and lane 11 in (b) of Figure 7D]. This ﬁnding may
result from a weak clamping ability, suﬃcient to
enhance intracellular transcriptional activity, but not suf-
ﬁcient to hold the protein–DNA complex in EMSA. This
mutant had one complete and one incomplete CP2c/
CP2b-interacting region (Figure 6A). Thus, our overall
ﬁndings suggest that PIAS1 acts as a clamp joining
CP2c and CP2b to enhance DNA-binding activity and
activate transcriptional potential and that this clamping
function also requires both of two CP2c/CP2b-interacting
regions, located in the N- and C-terminal regions of
PIAS1, respectively.
DISCUSSION
Erythroid-speciﬁc a-globin expression requires formation
of the CBP complex
Previously, we identiﬁed CP2c, CP2b and PIAS1 as
factors essential for a-globin gene expression in erythroid
cells (14). We found that all three proteins bind to the
endogenous a-globin promoter and that the extent of
binding increased in diﬀerentiating MEL cells. Even in
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and PIAS1 activated an exogenous a-globin promoter.
In this study, we conﬁrmed that CP2c, CP2b and PIAS1
are indispensable for erythroid-speciﬁc a-globin expres-
sion (Figure 1). The strong transactivation eﬀects of
CP2c, CP2b and PIAS1 decreased in a dose-dependent
manner with expression of shRNA speciﬁc for CP2
isoforms (CP2ci or CP2a/bi) or PIAS1 (PIAS1i)
(Figure 1A). Knockdown of CP2c, CP2b or PIAS1
reduced the transcriptional activity of an exogenous
a-globin promoter in diﬀerentiating MEL cells to the
levels found in undiﬀerentiated cells (Figure 1B), and sig-
niﬁcantly reduced endogenous a-globin gene expression in
diﬀerentiating MEL cells (Figure 1C). Thus, CP2c, CP2b
and PIAS1 are all required for a-globin gene expression in
diﬀerentiating MEL cells.
To understand the molecular mechanisms for
PIAS1-mediated a-globin gene expression, we ﬁrst tested
the subcellular localization of PIAS1. Exogenous PIAS1
itself localized in the nucleus and could recruit CP2c from
the cytosol to the nucleus, as did CP2b (14). In 293T cells,
exogenous PIAS1 clearly enhanced nuclear localization of
CP2c, whereas exogenous CP2c remained largely in the
cytosol (80%) (Figure 2B). In 293T cells with knockdown
of the human CP2a/b (LBP-1a/b), exogenous PIAS1 still
recruited CP2c to the nucleus. Thus, CP2b and PIAS1
appear to recruit CP2c to the nucleus by separate
pathways. Indeed, knockdown of either CP2a/b or
PIAS1 with siRNA reduced nuclear localization of CP2c
in both MEL and K562 cells, and knockdown of both
CP2a/b and PIAS1 reduced nuclear residency of CP2c
more severely (Figure 3). These ﬁndings indicate that
PIAS1 and CP2b recruit CP2c to the nucleus in an
additive manner via separate pathways.
PIAS1 revealed the additional function of recruiting the
CP2c/CP2b complex to the a-globin promoter. In the
EMSA (Figure 4), we found that the mobility shift of
the a-globin promoter accounted for the retention of
CP2c, CP2b and PIAS1 proteins together. However, the
mobility shift with all three recombinant proteins was
essentially identical to that seen with CP2c alone
(Figure 4A), even though one would expect an additional
mobility shift if all three proteins were involved in the
protein–DNA complex. One would also argue that
PIAS1 is more likely to function by sequestering CP2b
away from CP2c so that CP2c itself can restore its
DNA-binding activity. However, we conﬁrmed that all
three factors coexist in the mobility shift, as demonstrated
by supershift assays using factor-speciﬁc antibodies
(Figure 4B). This result was repeated in the reaction
using MEL cell extracts. Furthermore, all factors
mutually interact among themselves, as revealed by
Co-IP assays (Figure 4C). Thus, we anticipate that the
mobility shift with all three proteins represents a stoichi-
ometry diﬀerent from that with CP2c alone, despite nearly
identical gel migration. We found additional evidence that
the three proteins associate to form a single complex.
First, association of all three factors at the endogenous
a-globin promoter increased during MEL cell diﬀerenti-
ation (Figure 5A). Second, depletion of endogenous
PIAS1 in the diﬀerentiating MEL cells by siRNA
transfection reduced the association of both CP2c and
CP2b with the endogenous a-globin promoter (Figure
5B). These data together suggest that the three factors
associate and act together concertedly.
Finally, we found that PIAS1 physically holds CP2c
and CP2b together at the promoter. We identiﬁed two
separable binding regions in each protein component of
the CBP complex (Figure 6). Because we just showed
pair-wise interactions in this experiment, one may argue
that we did not test simultaneous interaction among them.
Nevertheless, both of the two CP2-binding regions of
PIAS1 were required, though not suﬃcient, for the
clamping function as revealed by EMSA and reporter
assays, whereas either CP2 binding region was suﬃcient
to mobilize CP2c to the nucleus and to sequester CP2
proteins from the promoter (Figure 7).
Based on our ﬁndings, we propose a model for the role
of PIAS1 in transcriptional activation of the a-globin gene
in erythroid cells (Figure 8). PIAS1 serves a dual function
in erythroid cell-speciﬁc globin gene transcription, i.e.
nuclear translocation of CP2c and formation of the
active CBP complex, by clamping the CBP components
together. The action may plausibly proceed, as follows:
CP2b and PIAS1, though localized in the nucleus,
cannot act by themselves on the a-globin promoter
because they cannot bind to the DNA (14). CP2c is re-
cruited into the nucleus by PIAS1 and CP2b in response to
a diﬀerentiation signal. CP2 isoforms form homo- and/or
heterodimers through the dimerization/oligomerization
domain in their C-terminal half (16,17). As a dimer or
oligomer, CP2c can bind directly to the target DNA
using its own DNA-binding domain (14). PIAS1 can
interact with both CP2b and CP2c through two regions,
located in its N- and C-termini. In the absence of PIAS1,
CP2b may interact with CP2c to form an unstable
protein–DNA complex (which may explain its ability to
exclude CP2c from the mobility shift assay). However,
PIAS1 clamps CP2b and CP2c together to form an
active CBP complex, thus, stabilizing its binding to
the a-globin promoter. Since stable DNA binding
requires a CP2c dimer, as well as simultaneous interaction
of PIAS1 with two CP2 proteins, the minimal protein
complex containing CP2c, CP2b and PIAS1 on the
a-globin promoter may be hexametric with two units
each of three proteins.
Functional signiﬁcance of the PIAS1-mediated CBP
complex formation
We have demonstrated that PIAS1 enhances
DNA-binding activity of the CP2c/CP2b complex to the
CP2 consensus sequences, in which PIAS1 functions as a
clamp to hold together CP2c and CP2b in a
sumoylation-independent manner (Figures 4 and 7).
Other transcription factors with regulation independent
of the sumoylating functions of PIAS include STAT1,
STAT3, NF- B and COUP-TF1 (19,39,40). However,
the clamping function of PIAS1 in transcription factor
regulation is not yet fully explored. Two separate
regions in each factor were involved in the interactions
between CP2 isoforms and PIAS1 (Figure 6).
5468 Nucleic Acids Research, 2010,Vol.38, No. 16The N-terminal CP2 binding region of PIAS1 overlapped
with the scaﬀold attachment factor-A/B/acinus/PIAS
(SAP) motif, whereas the C-terminal CP2c binding
region includes the SUMO-interacting motif (SIM), and
the C-terminal CP2b binding region requires additional
Ser/Thr-rich sequences.
We also showed here that PIAS1 mobilizes CP2c from
the cytoplasm to the nucleus (Figure 2). Reports indicate
that PIAS proteins eﬀect subnuclear localization of targets
without sumoylation activity. For instance, PIASy directs
the Wnt/b-catenin mediator LEF1 to PML nuclear bodies,
which results in repression of LEF1 activity (29). PIASy
potently inhibits Oct4-mediated transcriptional activation,
sequestering Oct4 protein from the vicinity of Cajal bodies
and splicing speckles at the nuclear periphery (41). Other
PIAS family members, PIAS1 and PIAS3, also interact
with Oct4 in vivo, and target Oct4 to the nuclear periphery
in a cell-type speciﬁc manner. The homeoprotein Msx1
moves to the nuclear periphery by the action of PIAS1,
which allows Msx1 to bind and repress the MyoD and
Myf5 gene promoters (42). These examples show that
the PIAS proteins, in a manner similar to our ﬁndings in
this report, can alter the subnuclear localization of target
transcription factors in a sumoylation-independent
manner through speciﬁc protein–protein interactions.
However, these examples represent transcriptional repres-
sion rather than activation, as observed in this study.
Implications of the CBP protein complex in erythroid
cell-speciﬁc gene expression
Erythroid diﬀerentiation depends vitally on CP2c binding
to consensus sequences in both the a- and b-globin
gene promoters and consequent activation of the genes
(13,43). In addition, CP2c regulation of human globin
gene expression correlates with putative CP2-binding se-
quences identiﬁed in the promoters of human a-, "-, g- and
b-globin genes (43). Mutations in GATA-1 and
CP2-binding sites within the promoter of the
uroporphyrinogen III synthase gene, the fourth enzyme
in the heme biosynthetic pathway, may cause congenital
erythropoietic porphyria (44). The CP2c/CP2b complex
binds in diﬀerent patterns depending on the cellular
context; for example, CP2b enhances CP2c binding to
consensus sites in K562 cells, but inhibits it in 293T cells
(14). These ﬁndings suggest that nuclear redistribution of
CP2c protein by PIAS1 and other CP2 members, and for-
mation of an active CBP complex through cooperative
interaction between PIAS1 and CP2 proteins represent
key regulatory steps in erythroid cell hemoglobin synthe-
sis. Similar regulatory patterns occur in the expression of
marker genes in smooth muscle cell (SMC) diﬀerentiation.
Serum response factor (SRF) mediates the expression
of most SMC diﬀerentiation marker genes through co-
operative interactions with myocardin, an SMC/
cardiomyocyte-speciﬁc SRF coactivator and through
binding to highly conserved CArG elements in
SMC-speciﬁc promoters (45–48). Through cooperative
interactions with both SRF and class I bHLH proteins,
PIAS1 also modulates transcriptional activation of SMC
marker genes (49). These ﬁndings suggest that PIAS1 and
CP2 proteins help to synchronize erythroid marker gene
expression, which might be tested by analysis of putative
target genes containing CP2 consensus sites.
The regulation of globin gene expression by an active
CBP complex presents a novel paradigm for understand-
ing the complex, but highly precise regulation of,
tissue-speciﬁc mammalian gene expression. Important
elements include the diversity of CP2 isoforms involved
in transactivation, DNA binding and heteromerization,
control of subcellular localization and interaction with
speciﬁc partner proteins, like PIAS1, in addition to
changes in the expression levels (1).
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Figure 8. A model of the CP2c/CP2b/PIAS1 complex activating a-globin gene expression. CP2c and CP2a localize mainly in the cytoplasm, whereas
CP2b and PIAS1 co-localize in the nucleus. A speciﬁc diﬀerentiation cue may increase the amount and/or activity of CP2b and PIAS1, inducing
movement of CP2c to the nucleus. Components of the hexametric CP2c/CP2b/PIAS1 complex, through a concerted interaction, strongly enhance
binding to the a-globin gene promoter and a-globin transcription in erythroid cells.
Nucleic Acids Research, 2010,Vol.38, No. 16 5469SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
ACKNOWLEDGEMENTS
We appreciate the help and advice of our colleagues at
the Laboratory of Molecular Genetics, Department of
Life Science, Hanyang University. Special thanks go to
M.-A. Park and J. J. Lee for their technical support. We
also thank Dr Guntram Suske (Philipps-University of
Marburg, Germany), Dr Wilson Xu (Memorial
Sloan-Kettering Cancer Center and Graduate School of
Medical Sciences, Cornell University, USA) and
Dr Didier Trono (University of Geneva, Switzerland)
for their gifts of plasmids or reagents.
FUNDING
A Korea Research Foundation Grant funded by the
(MOEHRD), Republic of Korea (KRF-2007-313-
C00594); the 2002 Research and Developmental Project
on Bio-Health of the Ministry of Health and Welfare,
Republic of Korea (No. 02-PJ10-PG8-EC01-0012); and
the Brain Korea 21 Project (to J.H.C. and J.J.), in part,
from the MOEHRD, through the Research Team for
Mammalian Development and Diﬀerentiation. Funding
for open access charge: Hanyang University.
Conﬂict of interest statement. None declared.
REFERENCES
1. Veljkovic,J. and Hansen,U. (2004) Lineage-speciﬁc and ubiquitous
biological roles of the mammalian transcription factor LSF. Gene,
343, 23–40.
2. Jane,S.M., Ney,P.A., Vanin,E.F., Gumucio,D.L. and
Nienhuis,A.W. (1992) Identiﬁcation of a stage selector element in
the human gamma-globin gene promoter that fosters preferential
interaction with the 50 HS2 enhancer when in competition with
the beta-promoter. EMBO J., 11, 2961–2969.
3. Zhou,W., Clouston,D.R., Wang,X., Cerruti,L., Cunningham,J.M.
and Jane,S.M. (2000) Induction of human fetal globin gene
expression by a novel erythroid factor, NF-E4. Mol. Cell. Biol.,
20, 7662–7672.
4. Zhou,W., Zhao,Q., Sutton,R., Cumming,H., Wang,X., Cerruti,L.,
Hall,M., Wu,R., Cunningham,J.M. and Jane,S.M. (2004) The role
of p22 NF-E4 in human globin gene switching. J. Biol. Chem.,
279, 26227–26232.
5. Bose ` ,F., Fugazza,C., Casalgrandi,M., Capelli,A.,
Cunningham,J.M., Zhao,Q., Jane,S.M., Ottolenghi,S. and
Ronchi,A. (2006) Functional interaction of CP2 with GATA-1 in
the regulation of erythroid promoters. Mol. Cell. Biol., 26,
3942–3954.
6. Bruni,P., Minopoli,G., Brancaccio,T., Napolitano,M.,
Faraonio,R., Zambrano,N., Hansen,U. and Russo,T. (2002) Fe65,
a ligand of the Alzheimer’s beta-amyloid precursor protein,
blocks cell cycle progression by down-regulating thymidylate
synthase expression. J. Biol. Chem., 277, 35481–35488.
7. Zambrano,N., Minopoli,G., Candia,P. and Russo,T. (1998) The
Fe65 adaptor protein interacts through its PID1 domain with the
transcription factor CP2/LSF/LBP1. J. Biol. Chem., 273,
20128–20133.
8. Barnhart,K.M., Kim,C.G., Banerji,S.S. and Sheﬀery,M. (1988)
Identiﬁcation and characterization of multiple erythroid cell
proteins that interact with the promoter of the murine
alpha-globin gene. Mol. Cell. Biol., 8, 3215–3226.
9. Kim,C.G., Barnhart,K.M. and Sheﬀery,M. (1988) Puriﬁcation of
multiple erythroid cell proteins that bind the promoter of the
a-globin gene. Mol. Cell. Biol., 8, 4270–4281.
10. Kim,C.G., Swendeman,S.L., Barnhart,K.M. and Sheﬀery,M.
(1990) Promoter-elements and erythroid cell nuclear factors that
regulate a-globin gene transcription in vitro. Mol. Cell. Biol., 10,
5958–5966.
11. Lim,L.C., Fang,L., Swendeman,S.L. and Sheﬀery,M. (1993)
Characterization of the molecularly cloned murine alpha-globin
transcription factor CP2. J. Biol. Chem., 268, 18008–18017.
12. Lim,L.C., Swendeman,S.L. and Sheﬀery,M. (1992) Molecular
cloning of the alpha-globin transcription factor CP2. Mol. Cell.
Biol., 12, 828–835.
13. Chae,J.H., Lee,Y.H. and Kim,C.G. (1999) Transcription factor
CP2 is crucial in hemoglobin synthesis during erythroid terminal
diﬀerentiation in vitro. Biochem. Biophys. Res. Commun., 263,
580–583.
14. Kang,H.C., Chae,J.H., Lee,Y.H., Park,M.A., Shin,J.H., Kim,S.H.,
Ye,S.K., Cho,Y.S., Fiering,S. and Kim,C.G. (2005) Erythroid
cell-speciﬁc alpha-globin gene regulation by the CP2 transcription
factor family. Mol. Cell. Biol., 25, 6005–6020.
15. Chae,J.H., Kang,H.C. and Kim,C.G. (2009) The relative cellular
levels of CP2a and CP2b potentiates erythroid cell-speciﬁc
expression of the a-globin gene by regulating the nuclear
localization of CP2c. Biochem. Biophys. Res. Commun., 380,
813–817.
16. Uv,A.E., Thompson,C.R. and Bray,S.J. (1994) The Drosophila
tissue-speciﬁc factor Grainyhead contains novel DNA-binding and
dimerization domains which are conserved in the human protein
CP2. Mol Cell Biol., 14, 4020–4031.
17. Shirra,M.K., Zhu,Q., Huang,H.C., Pallas,D. and Hansen,U.
(1994) One exon of the human LSF gene includes conserved
regions involved in novel DNA-binding and dimerization motifs.
Mol. Cell Biol., 14, 5076–5087.
18. Shuai,K. and Liu,B. (2005) Regulation of gene-activation
pathways by PIAS proteins in the immune system. Nat. Rev.
Immunol., 5, 593–605.
19. Chung,C.D., Liao,J., Liu,B., Rao,X., Jay,P., Berta,P. and
Shuai,K. (1997) Speciﬁc inhibition of Stat3 signal transduction by
PIAS3. Science, 278, 1803–1805.
20. Liu,B., Liao,J., Rao,X., Kushner,S.A., Chung,C.D., Chang,D.D.
and Shuai,K. (1998) Inhibition of Stat1-mediated gene activation
by PIAS1. Proc. Natl. Acad. Sci. USA, 95, 10626–1031.
21. Schmidt,D. and Mu ¨ ller,S. (2003) PIAS/SUMO: new
partners in transcriptional regulation. Cell. Mol. Life Sci., 60,
2561–2574.
22. Sharrocks,A.D. (2006) PIAS proteins and transcriptional
regulation–more than just SUMO E3 ligases? Genes Dev., 20,
754–758.
23. O’Shea,J.J. and Watford,W. (2004) A peek at PIAS.
Nat. Immunol., 5, 875–876.
24. Jackson,P.K. (2001) A new RING for SUMO: wrestling
transcriptional responses into nuclear bodies with PIAS family E3
SUMO ligases. Genes Dev., 15, 3053–3058.
25. Weger,S., Hammer,E. and Heilbronn,R. (2004) SUMO-1
modiﬁcation regulates the protein stability of the large regulatory
protein Rep78 of adeno associated virus type 2 (AAV-2).
Virology, 330, 284–294.
26. Besnault-Mascard,L., Leprince,C., Auﬀredou,M.T., Meunier,B.,
Bourgeade,M.F., Camonis,J., Lorenzo,H.K. and Vazquez,A.
(2005) Caspase-8 sumoylation is associated with nuclear
localization. Oncogene, 24, 3268–3273.
27. Pichler,A. and Melchior,F. (2002) Ubiquitin-related modiﬁer
SUMO1 and nucleocytoplasmic transport. Traﬃc, 3, 381–387.
28. Kahyo,T., Nishida,T. and Yasuda,H. (2001) Involvement of
PIAS1 in the sumoylation of tumor suppressor p53. Mol. Cell, 8,
713–718.
29. Sachdev,S., Bruhn,L., Sieber,H., Pichler,A., Melchior,F. and
Grosschedl,R. (2001) PIASy, a nuclear matrix-associated SUMO
E3 ligase, represses LEF1 activity by sequestration into nuclear
bodies. Genes Dev., 15, 3088–3103.
30. Kotaja,N., Karvonen,U., Ja ¨ nne,O.A. and Palvimo,J.J. (2002)
PIAS proteins modulate transcription factors by functioning as
SUMO-1 ligases. Mol. Cell. Biol., 22, 5222–5234.
5470 Nucleic Acids Research, 2010,Vol.38, No. 1631. Girdwood,D.W., Tatham,M.H. and Hay,R.T. (2004) SUMO and
transcriptional regulation. Semin. Cell Dev. Biol., 15, 201–210.
32. Ilmarinen,T., Kangas,H., Kyto ¨ maa,T., Eskelin,P., Saharinen,J.,
Seeler,J.S., Tanhuanpa ¨ a ¨ ,K., Chan,F.Y., Slattery,R.M.,
Alakurtti,K. et al. (2008) Functional interaction of AIRE with
PIAS1 in transcriptional regulation. Mol. Immunol., 45,
1847–1862.
33. Diao,Y., Wang,X. and Wu,Z. (2009) SOCS1, SOCS3, and PIAS1
promote myogenic diﬀerentiation by inhibiting the leukemia
inhibitory factor-induced JAK1/STAT1/STAT3 pathway. Mol.
Cell Biol., 29, 5084–5093.
34. Forsberg,E.C., Downs,K.M., Christensen,H.M., Im,H., Nuzzi,P.A.
and Bresnick,E.H. (2000) Developmentally dynamic histone
acetylation pattern of a tissue-speciﬁc chromatin domain.
Proc. Natl Acad. Sci. USA, 97, 14494–14499.
35. Chen,L.F. and Greene,W.C. (2003) Regulation of distinct
biological activities of the NF-kappaB transcription factor
complex by acetylation. J. Mol. Med., 81, 549–557.
36. Duma,D., Jewell,C.M. and Cidlowski,J.A. (2006) Multiple
glucocorticoid receptor isoforms and mechanisms of
post-translational modiﬁcation. J. Steroid Biochem. Mol. Biol.,
102, 11–21.
37. Schwoebel,E.D. and Moore,M.S. (2000) The control of gene
expression by regulated nuclear transport. Essays Biochem., 36,
105–113.
38. Kotaja,N., Karvonen,U., Ja ¨ nne,O.A. and Palvimo,J.J. (2002)
PIAS proteins modulate transcription factors by functioning as
SUMO-1 ligases. Mol Cell Biol., 22, 5222–5234.
39. Liu,B., Yang,R., Wong,K.A., Getman,C., Stein,N., Teitell,M.A.,
Cheng,G., Wu,H. and Shuai,K. (2005) Negative regulation
of NF-kappaB signaling by PIAS1. Mol. Cell. Biol., 25,
1113–1123.
40. Kurihara,I., Shibata,H., Kobayashi,S., Suda,N., Ikeda,Y.,
Yokota,K., Murai,A., Saito,I., Rainey,W.E. and Saruta,T. (2005)
Ubc9 and protein inhibitor of activated STAT 1 activate chicken
ovalbumin upstream promoter-transcription factor I-mediated
human CYP11B2 gene transcription. J. Biol. Chem., 280,
6721–6730.
41. Tolkunova,E., Malashicheva,A., Parfenov,V.N., Sustmann,C.,
Grosschedl,R. and Tomilin,A. (2007) PIAS proteins as repressors
of Oct4 function. J. Mol. Biol., 374, 1200–1212.
42. Lee,H., Quinn,J.C., Prasanth,K.V., Swiss,V.A., Economides,K.D.,
Camacho,M.M., Spector,D.L. and Abate-Shen,C. (2006) PIAS1
confers DNA-binding speciﬁcity on the Msx1 homeoprotein.
Genes Dev., 20, 784–794.
43. Chae,J.H. and Kim,C.G. (2003) CP2 binding to the promoter is
essential for the enhanced transcription of globin genes in
erythroid cells. Mol. Cells, 15, 40–47.
44. Solis,C., Aizencang,G.I., Astrin,K.H., Bishop,D.E. and
Desnick,R. (2001) Uroporphyrinogen III synthase erythroid
promoter mutations in adjacent GATA1 and CP2 elements cause
congenital erythropoietic porphyria. J. Clin. Invest., 107, 753–762.
45. Kim,S., Ip,H.S., Lu,M.M., Clendenin,C. and Parmacek,M.S.
(1997) A serum response factor-dependent transcriptional
regulatory program identiﬁes distinct smooth muscle cell
sublineages. Mol. Cell. Biol., 17, 2266–2278.
46. Li,L., Miano,J.M., Mercer,B. and Olson,E.N. (1996) Expression
of the SM22 promoter in transgenic mice provides evidence for
distinct transcriptional regulatory programs in vascular and
visceral smooth muscle cells. J. Cell Biol., 132, 849–859.
47. Mack,C.P. and Owens,G.K. (1999) Regulation of smooth muscle
a-actin expression in vivo is dependent on CArG elements within
the 50 and ﬁrst intron promoter regions. Circ. Res., 84, 852–861.
48. Yoshida,T., Kawai-Kowase,K. and Owens,G.K. (2004) Forced
expression of myocardin is not suﬃcient for induction of smooth
muscle diﬀerentiation in multipotential embryonic cells.
Arterioscler. Thromb. Vasc. Biol., 24, 1596–1601.
49. Kawai-Kowase,K., Kumar,M.S., Hoofnagle,M.H., Yoshida,T. and
Owens,G.K. (2005) PIAS1 activates the expression of smooth
muscle cell diﬀerentiation marker genes by interacting with serum
response factor and class I basic helix-loop-helix proteins.
Mol. Cell. Biol., 25, 8009–8023.
Nucleic Acids Research, 2010,Vol.38, No. 16 5471